Latham & Watkins represented Revolution Medicines, while Davis Polk advised the underwriters in the offering.Revolution Medicines, Inc. (Nasdaq: RVMD), has announced the pricing of its underwritten public…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
